Pioneering mRNA technology - Moderna
Moderna's mission is to deliver the greatest possible impact to people through mRNA medicines.
Our Story - Moderna
We’re making biotech history. Since 2010, we have worked to build the industry's leading mRNA technology platform. Learn more about Moderna’s history.
Company Culture - Moderna
Join Moderna as we pursue the uncharted reaches of possibility and make your mark on the future of medicine.
Investor Relations Overview - Moderna
Overview of Moderna news, events & presentations, latest quarterly results, and Moderna's pipeline development programs.
Our Mission & Values - Moderna
Moderna people hold a deep sense of responsibility for each other, patients, the environment and our local communities. Our people live our Values every day.
mRNA medicines we are currently developing - Moderna
Track the development of Moderna’s mRNA medicines. From preclinical development to commercial phase.
Moderna's mRNA Platform - Moderna
The mRNA DESIGN STUDIO integrates with Moderna’s automation platforms – directing orders through each phase of mRNA synthesis. Once the order is placed, Moderna’s high-throughput mRNA pre-clinical production facility manages the manufacturing of mRNA constructs and delivers them in just weeks.
Moderna Advances Multiple Vaccine Programs to Late-Stage …
2024年3月27日 · Moderna is advancing five vaccine candidates against viruses that cause latent infections, all of which are in clinical trials. When latent, a virus is present in the body but exists in a resting state, typically without causing any noticeable symptoms.
Moderna Achieves Positive Interim Results from Phase 3 Trial of …
2024年3月26日 · CAMBRIDGE, MA / ACCESSWIRE / March 26, 2024 / Moderna, Inc. (NASDAQ:MRNA) today announced that mRNA-1283, the Company's next-generation COVID-19 vaccine, has successfully met the primary endpoints of its Phase 3 clinical trial, demonstrating a higher immune response against SARS-CoV-2 when compared to mRNA-1273.222, Moderna's licensed COVID-19 ...
Moderna Receives U.S. FDA Approval for Updated COVID-19 Vaccine
2023年9月11日 · Moderna's updated COVID-19 vaccine contains spike proteins for the XBB.1.5 sublineage of SARS-CoV-2 to help prevent COVID-19 in individuals 6 months of age and older. With the U.S. FDA's decision, Moderna will begin shipping doses to vaccination sites across the U.S., with updated vaccines expected to be available in the coming days.